Escalate Capital Partners β 2014 Investments
4 investments dated 2014 Β· listed companies and verified rows first Β· show all
Phreesia provides a patient intake and engagement platform with automated tools for registration, insurance verification, appointment access, and payments used by healthcare organizations.
Digital HealthHealthtechSaaSNew York, US
Chaim Indig(Executive Officer, Director)Charles Kallenbach(Executive Officer)Thomas Altier(Executive Officer)Michael Weintraub(Director)Victor Kats(Director)Dusty Lieb(Director)
Co-investorsAscension VenturesBlue Venture FundsHLM Venture PartnersLLRLRVHealthVantagePoint Capital Partners
CompStak is a crowdsourced commercial real estate data platform that aggregates millions of data points weekly to provide comprehensive CRE datasets for lenders, investors, and landlords.
Data & InfrastructureEnterprise SoftwarePropTechNew York, US
Michael Mandel(Co-founder & CEO)inVadim Belobrovka(Co-founder & CTO)Hrach Simonian(Director)
Co-investorsCamber CreekCanaan PartnersExpansion Venture CapitalFounder CollectiveGlobal BrainIA Capital Group+3 more
Dstillery provides an AI-powered audience targeting platform for programmatic digital advertising, using predictive modeling to build campaign audiences from a brief to activation.
AdTechAI & Machine LearningMarketing TechNew York, US
Paul Matteucci(Director)Andrew Pancer(Executive Officer)Michael DiPiano(Director)Alan Murray(Executive Officer, Director)David Bell(Director)Mark Siegel(Director)
Co-investorsContour Venture PartnersProgress VenturesUS Venture PartnersNewSpring Capital
Revionics provides AI-driven pricing and merchandising optimization software for retailers, using proprietary algorithms to set optimal prices across the pricing lifecycle.
AI & Machine LearningRetail TechSaaSRoseville, US
Jeff smith(Founder)inJoel G. Katz(Director)Marc H. Hafner(Executive Officer, Director)Brian K. Hansen(Executive Officer)Hillel Moerman(Director)David Schwab(Director)
Co-investorsBlumberg CapitalGoldman Sachs
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.